How is the Non-Proliferative Diabetic Retinopathy Market Poised for Growth: Trends and Opportunities Through 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the non-proliferative diabetic retinopathy market grown over the years?
In recent times, there has been robust growth in the market size of non-proliferative diabetic retinopathy. It is projected to escalate from $2.62 billion in 2024 to a figure of $2.84 billion in 2025, at a compound annual growth rate (CAGR) of 8.4%. This growth in the past can be attributed to various factors such as the rising incidence of diabetes, aging population, enhanced awareness, advances in research, changes in lifestyle and improved management of diabetes.
What Is the forecasted market size and growth rate for the non-proliferative diabetic retinopathy market?
In the coming years, the non-proliferative diabetic retinopathy market is expected to witness robust growth, projected to reach $3.87 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this growth during the prediction period include the embrace of telemedicine, the creation of new therapies, the implementation of artificial intelligence, an increase in research and development funding, and the improvement of healthcare facilities. Key trends for the forecast period encompass the increased use of artificial intelligence for screening and diagnosis, a surge in demand for telemedicine, and remote monitoring solutions, the advent of individualized medicine strategies for diabetic retinopathy treatment, heightened emphasis on prevention tactics and early intervention, as well as the growing significance of patient-centered care models in managing diabetic retinopathy.
Get your non-proliferative diabetic retinopathy market report here!
What are the major factors driving growth in the non-proliferative diabetic retinopathy market?
The growth of the non-proliferative diabetic retinopathy market is anticipated to be driven by the rising occurrence of diabetes. This chronic metabolic disorder is defined by high blood glucose levels due to insufficient insulin production by the pancreas, or the cells of the body developing resistance to insulin effects. Diabetes results from factors like sedentary lifestyles, poor dietary habits, and genetic predispositions. Non-proliferative diabetic retinopathy is triggered by diabetes through damaging the retina’s blood vessels, mainly due to long-term exposure to high bloodstream glucose levels, causing vision problems and possible blindness. For example, the National Health Service, based in the UK, reported in June 2024 that in 2023, over half a million (549,000) new individuals in England were found to be at risk of developing type 2 diabetes. This increased the total number of non-diabetic hyperglycemia or pre-diabetes cases registered with a GP to 3,615,330. This is a substantial increase compared to the 3,065,825 cases in 2022, constituting a nearly 20% increase. Consequently, the escalating prevalence of diabetes is a major driving factor for the growth of the non-proliferative diabetic retinopathy market.
What key areas define the segmentation of the global non-proliferative diabetic retinopathy Market?
The non-proliferative diabetic retinopathy market covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (Ppv), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
What are the top market players propelling the growth of the non-proliferative diabetic retinopathy industry?
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.
Which trends are expected to transform the non-proliferative diabetic retinopathy market?
Leading businesses in the non-proliferative diabetic retinopathy market are advancing ophthalmic imaging by utilizing AI-enabled cameras to enhance patient results. These cameras are integrated with AI algorithms to help capture, scrutinize, and interpret eye images for both diagnostic and therapeutic intent. For example, in May 2024, Optomed, a medical technology enterprise situated in Finland, introduced its Optomed Aurora AEYE. This handheld AI fundus camera, designed to instantly identify more than just mild diabetic retinopathy, seamlessly merges the convenience of a handheld camera with the potency of AI to generate high-grade retinal images for the early detection and tracking of varied eye conditions. The Optomed Aurora AEYE leverages AI algorithms for enabling healthcare experts to evaluate retinal images effectively. This facilitates prompt and precise diagnoses of conditions like diabetic retinopathy, glaucoma, or age-related macular degeneration.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15620
What regions are dominating the non-proliferative diabetic retinopathy market growth?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Diabetic Kidney Disease Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report
Diabetic Foot Ulcer Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-global-market-report
Diabetic Retinopathy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
